Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTI-101 in HPV-negative Squamous Cell Carcinoma of the Head and Neck
NCT05845307Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised trial of tti-101 in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of Adverse Events and Change in pY-STAT3 H-score in tumor tissue. Planned start Jun 2025; status: withdrawn.
02
Drugs
tti-101
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05845307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05845307.